Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $7.8000 (-1.64%) ($7.6400 - $8.0600) on Wed. Nov. 20, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.86% (three month average) | RSI | 72 | Latest Price | $7.8000(-1.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -0.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.1% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(58%) IBB(57%) ARKK(56%) IWO(56%) | Factors Impacting TGTX price | TGTX will decline at least -1.93% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-7%) TLT(-7%) IGOV(-1%) | | | | | Relative Volatility | | | | Market Trend Strength | -1.93% (StdDev 3.86%) | Hourly BBV | 0 () | Intraday Trend | -1.5% | | | |
|
5 Day Moving Average | $7.93(-1.64%) | 10 Day Moving Average | $7.89(-1.14%) | 20 Day Moving Average | $7.41(5.26%) | To recent high | -4.5% | To recent low | 52.9% | Market Cap | $988m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |